Rationally designed anti-HER2/neu peptide mimetic disables p185(HER2/neu) tyrosine kinases in vitro and in vivo

Nature Biotechnology

Volumn 18, Issue 2, 2000, Pages 194-198

  Park, Byeong Woo ^a   Zhang, Hong Tao ^a   Wu, Chuanjin ^a   Berezov, Alan ^a   Zhang, Xin ^a   Dua, Raj ^b   Wang, Qiang ^a   Kao, Gary ^a   O'Rourke, Donald M ^a   Greene, Mark I ^a   Murali, Ramachandran ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b International Therapeutics Inc   (United States)

Author keywords

radiation; Doxorubicin; ErbB2; Her2; Herceptin; Mimetic; Neu; Tumor therapy

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CELL COMPARTMENTALIZATION; COLONY FORMATION; EXOCYTOSIS; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BIOSENSING TECHNIQUES; DOXORUBICIN; DRUG DESIGN; DRUG THERAPY, COMBINATION; GAMMA RAYS; MICE; MICE, NUDE; MOLECULAR MIMICRY; PROTEIN BINDING; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033953634     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/72651     Document Type: Article

References (43)

1. Slamon, D.J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
2. Cohen, J.A. et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4, 81-88 (1989).
3. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Development of monoclonal antibodies reactive with the product of the neu oncogene. Symp. Fund. Cancer Res. 38, 277-289 (1986).
4. Drebin, J.A., Link, V.C. & Greene, M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2, 387-394 (1988).
5. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998).
6. Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89, 4285-4289 (1992).
7. Fendly, B.M. et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550-1558 (1990).
8. Hudziak, R.M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9, 1165-1172 (1989).
9. Drebin, J.A., Stern, D.F., Link, V.C., Weinberg, R.A. & Greene, M.I. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312, 545-548 (1984).
10. Drebin, J.A., Link, V.C., Weinberg, R.A. & Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 83, 9129-9133 (1986).
11. Cho, M.J. & Juliano, R. Macramolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol. 14, 153-158 (1996).
12. Hruby, V.J. Conformational and topographical considerations in the design of biologically active peptides. Biopolymers 33, 1073-1082 (1993).
13. Langston, S. Peptidomimetics and small molecule design. Drug Discov. Today 2, 254-256 (1997).
14. Qabar, M., Urban, J., Sia, C., Klein, M. & Kahn, M. Pharmaceutical applications of peptidomimetics. Lett. Pept. Sci. 3, 25-30 (1996).
15. Murali, R. & Greene, M.I. Structure-based design of immunologically active therapeutic peptides. Immunol. Res. 17, 163-169 (1998).
16. Moore, G.J. Designing peptide mimetics. Trends Pharmacol. Sci. 15, 124-129 (1994).
17. KieberEmmons, T., Murali, R. & Greene, M.I. Therapeutic peptides and peptidomimetics. Curr. Opin. Biotechnol. 8, 435-441 (1997).
18. Saragovi, H.U. et al. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 253, 792-795 (1991).
19. Zhang, X. et al. Synthetic Cd4 exocyclic peptides antagonize Cd4 holoreceptor binding and T-cell activation. Nat. Biotechnol. 14, 472-475. (1996).
20. Takasaki, W., Kajino, Y., Kajino, K., Murali, R. & Greene, M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat. Biotechnol. 15, 1266-1270 (1997).
21. Chothia, C. & Lesk, A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917 (1987).
22. MacCallum, R.M., Martin, A.C. & Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262, 732-745 (1996).
23. Mariuzza, R.A., Phillips, S.E. & Poljak, R.J. The structural basis of antigen-antibody recognition. Annu. Rev. Biophys. Biophys. Chem. 16, 139-159 (1987).
24. Bruck, C. et al. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc. Natl. Acad. Sci. USA 83, 6578-6582 (1986).
25. Eigenbrot, C., Randal, M., Presta, L., Carter, P. & Kossiakoff, A.A. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. 229, 969-995 (1993).
26. Eigenbrot, C. et al. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65. Proteins 18, 49-62 (1994).
27. Zhang, H. et al. Pathobiological features of shared antigenic epitopes and biological functions of distinct and humanized anti-p185her2/neu monoclonal antibodies. Exp. Mol. Pathol. 67, 15-25 (1999).
28. Zhang, X. et al. Synthetic Cd4 exocyclics inhibit binding of human-immunodeficiency-virus type-1 envelope to Cd4 and virus-replication in T-lymphocytes. Nat. Biotechnol. 15, 150-154. (1997).
29. Adang, A.E.P., Hermkens, P.H.H., Linders, J.T.M., Ottenheijm, H.C.J. & van Staveren, C.J. Case histories of peptidomimetics: progression from peptides to drugs. Recl. Trav. Chim. Pays-Bas. 113, 63-78 (1994).
30. Akamatsu, M. et al. Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. Bioorg. Med. Chem. 5, 157-163 (1997).
31. Graciani, N.R., Tsang, K.Y., McCutchen, S.L. & Kelly, J.W. Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics. Bioorg. Med. Chem. 2, 999-1006 (1994).
32. McDonnell, J.M., Fushman, D., Cahill, S.M., Sutton, B.J. & Cowburn, D. Solution structures of Fc epsilon RI alpha-chain mimics: a beta-hairpin peptide and its retroenantiomer. J. Am. Chem. Soc. 119, 5321-5328 (1997).
33. Yiallouros, I. et al. Phosphinic peptides, the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors. Biochem. J. 331, 375-379 (1998).
34. Benveniste, M. & Mayer, M.L. Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction. Br. J. Pharmacol. 104, 207-221 (1991).
35. Moosmayer, D. et al. Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J. Interf. Cytok. Res. 16, 471-477 (1996).
36. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
37. Qian, X. et al. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. DNA Cell Biol. 16, 1395-1405 (1997).
38. Hansen, M.B., Nielsen, S.E. & Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203-210 (1989).
39. Shepard, H.M. et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. [Review]. J. Clin. Immunol. 11, 117-127 (1991).
40. O'Rourke, D.M. et al. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc. Natl. Acad. Sci. USA 95, 10842-10847 (1998).
41. Waldman, T. et al. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3, 1034-1036 (1997).
42. Katsumata, M. et al. Prevention of breast tumour development in vivo by down-regulation of the p185neu receptor. Nat. Med. 1, 644-648 (1995).
43. Qian, X., Dougall, W.C., Hellman, M.E. & Greene, M.I. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene 9, 1507-1514 (1994).